Brentuximab-based chemotherapy improves survival and reduces toxicity in patients with advanced Hodgkin lymphoma
1. BrECADD resulted in significantly lower treatment-related morbidity than eBEACOPP. 2. Progression-free survival at 48 months was significantly greater in ...
